The overall mean total was 3.7 ±6.1 days/3 months, representing a loss of 6.1% of productive days, of which 2.1 ±4.0 days/3 months were lost at home and 1.4 ±4.1 days/months were lost in the work place.
Four (13%) patients received less than 6 months of treatment, including two because of death at three and five months of treatment, and two that stopped their treatment after 3 months and were lost to follow-up, including one which eventually relapsed the following year.
Amongst the 107 subjects analysed at 3 months (seven were lost to follow-up), we report a significant greater reduction in the death group: 9.5 (10.3) vs 5.6 (9.9), mean difference 4.0 (0.1; 7.9).
At 24 months, 10% were lost to follow-up, with 17 subjects remaining in intensive medical therapy and 18 and 19 subjects remaining in the gastric bypass and sleeve gastrectomy groups, respectively.
During a median of 42.3 months (interquartile range 39.3 44.2 months), 16 (2.9 %) were lost to follow-up.
During a median of 42.3 months (interquartile range 39.3 44.2 months), 16 (2.9 %) were lost to follow-up, and patients experienced 69 (12.9 %) MACEs: 51 (9.6 %) all-cause deaths and 183.4.4 %) nonfatal myocardial infarction cases.
The exclusion criteria were acute kidney injury, defined as more than a 50% reduction in the eGFR within 3 months, patients who were lost to follow-up in less than 3 months (n = 90),CKD stage 1, 2 patients due to small sample size (n = 356) and CKD stage 5 patients.
At 12 months, four patients were lost to follow-up, and three changed their venue of primary care.
From sixth to ninth months, 11 participants were lost to follow-up and only 103 were available for the final analysis.
